Spark and Pfizer’s haemophilia gene therapy gets European PRIME status
cell and gene therapy, gene therapy, haemophilia B, Priority Medicines programme, Spark Therapeutics
0 Comment
Decision based on promising data from ongoing phase 1/2 trial.